


IN THE CLAIMS

Please cancel claims 15 and 17 without prejudice to their presentation in a continuation or divisional application.

Please replace claim 1 with the correspondingly numbered claim:

1 (Amended). A compound of the formula:



or a pharmaceutically acceptable salt, ester, solvate or prodrug thereof, wherein:

A₀ is an acyl group selected from:

- (1) R-(CH₂)_n-C(O)-; wherein n is an integer from 0 to 8 and R is selected from hydroxyl; methyl; N-acetylamino; methoxyl; carboxyl; cyclohexyl optionally containing a one or two double bonds and optionally substituted with one to three hydroxyl groups; and a 5- or 6-membered ring aromatic or nonaromatic ring optionally containing one or two heteroatoms selected from nitrogen, oxygen, and sulfur, wherein the ring is optionally substituted with a moiety selected from alkyl, alkoxy, and halogen; and
- (2) R¹-CH₂CH₂-(OCH₂CH₂O)_p-CH₂-C(O)-; wherein R¹ is selected from hydrogen, alkyl, and N-acetylamino, and p is an integer from 1 to 8;

A₁ is an amino acyl residue selected from:

- (1) alanyl,
- (2) asparaginyl,
- (3) citrullyl,
- (4) glutaminyl,
- (5) glutamyl,
- (6) N-ethylglycyl,
- (7) methionyl,
- (8) N-methylalanyl,

- Al*
- Cont.*
- (9) proyl,
 - (10) pyro-glutamyl,
 - (11) sarcosyl,
 - (12) seryl,
 - (13) threonyl,
 - (14) $-\text{HN}-(\text{CH}_2)_q-\text{C}(\text{O})-$, wherein q is 1 to 8, and
 - (15) $-\text{HN}-\text{CH}_2\text{CH}_2-(\text{OCH}_2\text{CH}_2\text{O})_r-\text{CH}_2-\text{C}(\text{O})-$, wherein r is 1 to 8;

A_2 is an amino acyl residue selected from:

- (1) alanyl,
- (2) asparaginyl,
- (3) aspartyl,
- (4) glutaminyl,
- (5) glutamyl,
- (6) leucyl,
- (7) methionyl,
- (8) phenylalanyl,
- (9) prolyl,
- (10) seryl,
- (11) $-\text{HN}-(\text{CH}_2)_q-\text{C}(\text{O})-$, wherein q is 1 to 8,
- (12) $-\text{HN}-\text{CH}_2\text{CH}_2-(\text{OCH}_2\text{CH}_2\text{O})_r-\text{CH}_2-\text{C}(\text{O})-$, wherein r is 1 to 8, and
- (13) glycyl;

A_3 is an amino acyl residue selected from:

- (1) alanyl,
- (2) asparaginyl,
- (3) citrullyl,
- (4) cyclohexylalanyl,
- (5) cyclohexylglycyl,
- (6) glutaminyl,
- (7) glutamyl,
- (8) glycyl,
- (9) isoleucyl,
- (10) leucyl,
- (11) methionyl,
- (12) norvalyl,

- A*
Conf
- (13) phenylalanyl,
 - (14) seryl,
 - (15) *t*-butylglycyl,
 - (16) threonyl,
 - (17) valyl,
 - (18) penicillaminy1, and
 - (19) cystyl;

A_4 is an amino acyl residue of L or D configuration selected from:

- (1) allo-isoleucyl,
- (2) glycyl,
- (3) isoleucyl,
- (4) prolyl,
- (5) dehydroleucyl,
- (6) D-alanyl,
- (7) D-3-(naphth-1-yl)alanyl,
- (8) D-3-(naphth-2-yl)alanyl,
- (9) D-(3-pyridyl)-alanyl,
- (10) D-2-aminobutyryl,
- (11) D-allo-isoleucyl,
- (12) D-allo-threonyl,
- (13) D-allylglycyl,
- (14) D-asparaginyl,
- (15) D-aspartyl,
- (16) D-benzothienyl,
- (17) D-3-(4,4'-biphenyl)alanyl,
- (18) D-chlorophenylalanyl,
- (19) D-3-(3-trifluoromethylphenyl)alanyl,
- (20) D-3-(3-cyanophenyl)alanyl,
- (21) D-3-(3,4-difluorophenyl)alanyl,
- (22) D-citrullyl,
- (23) D-cyclohexylalanyl,
- (24) D-cyclohexylglycyl,
- (25) D-cystyl,
- (26) D-cystyl(*S-t*-butyl),

- All
Done*
- (27) D-glutaminyl,
 - (28) D-glutamyl,
 - (29) D-histidyl,
 - (30) D-homoisoleucyl,
 - (31) D-homophenylalanyl,
 - (32) D-homoseryl,
 - (33) D-isoleucyl,
 - (34) D-leucyl,
 - (35) D-lysyl(N-epsilon-nicotinyl),
 - (36) D-lysyl,
 - (37) D-methionyl,
 - (38) D-neopentylglycyl,
 - (39) D-norleucyl,
 - (40) D-norvalyl,
 - (41) D-ornithyl,
 - (42) D-penicillaminyl,
 - (43) D-penicillaminyl(acetamidomethyl),
 - (44) D-penicillaminyl(S-benzyl),
 - (45) D-phenylalanyl,
 - (46) D-3-(4-aminophenyl)alanyl,
 - (47) D-3-(4-methylphenyl)alanyl,
 - (48) D-3-(4-nitrophenyl)alanyl,
 - (49) D-3-(3,4-dimethoxyphenyl)alanyl,
 - (50) D-3-(3,4,5-trifluorophenyl)alanyl,
 - (51) D-proyl,
 - (52) D-seryl,
 - (53) D-seryl(O-benzyl),
 - (54) D-t-butylglycyl,
 - (55) D-thienylalanyl,
 - (56) D-threonyl,
 - (57) D-threonyl(O-benzyl),
 - (58) D-tryptyl,
 - (59) D-tyrosyl(O-benzyl),
 - (60) D-tyrosyl(O-ethyl),

(61) D-tyrosyl, and

(62) D-valyl;

A₅ is an amino acyl residue of L or D configuration selected from:

- (1) alanyl,
- (2) (3-pyridyl)alanyl,
- (3) 3-(naphth-1-yl)alanyl,
- (4) 3-(naphth-2-yl)alanyl,
- (5) allo-threonyl,
- (6) allylglycyl,
- (7) glutaminyl,
- (8) glycyl,
- (9) histidyl,
- (10) homoseryl,
- (11) isoleucyl,
- (12) lysyl(N-epsilon-acetyl),
- (13) methionyl,
- (14) norvalyl,
- (15) octylglycyl,
- (16) ornithyl,
- (17) 3-(4-hydroxymethylphenyl)alanyl,
- (18) prolyl,
- (19) seryl,
- (20) threonyl,
- (21) tryptyl,
- (22) tyrosyl,
- (23) D-allo-threonyl,
- (24) D-homoseryl,
- (25) D-seryl,
- (26) D-threonyl,
- (27) penicillaminy, and
- (28) cystyl;

A₆ is an amino acyl residue of L or D configuration selected from:

- (1) alanyl,
- (2) 3-(naphth-1-yl)alanyl,

- Ad
Gm*
- (3) 3-(naphth-2-yl)alanyl,
 - (4) (3-pyridyl)alanyl,
 - (5) 2-aminobutyryl,
 - (6) allylglycyl,
 - (7) arginyl,
 - (8) asparaginyl,
 - (9) aspartyl,
 - (10) citrullyl,
 - (11) cyclohexylalanyl,
 - (12) glutaminyl,
 - (13) glutamyl,
 - (14) glycyl,
 - (15) histidyl,
 - (16) homoalanyl,
 - (17) homoleucyl,
 - (18) homoseryl,
 - (19) isoleucyl,
 - (20) leucyl,
 - (21) lysyl(N-epsilon-acetyl),
 - (22) lysyl(N-epsilon-isopropyl),
 - (23) methionyl(sulfone),
 - (24) methionyl(sulfoxide),
 - (25) methionyl,
 - (26) norleucyl,
 - (27) norvalyl,
 - (28) octylglycyl,
 - (29) phenylalanyl,
 - (30) 3-(4-carboxyamidephenyl)alanyl,
 - (31) propargylglycyl,
 - (32) seryl,
 - (33) threonyl,
 - (34) tryptyl,
 - (35) tyrosyl,
 - (36) valyl,

- Ans*
- Ans* ↴
- (37) D-3-(naphth-1-yl)alanyl,
 - (38) D-3-(naphth-2-yl)alanyl,
 - (39) D-glutaminyl,
 - (40) D-homoseryl,
 - (41) D-leucyl,
 - (42) D-norvalyl,
 - (43) D-seryl,
 - (44) penicillaminyI, and
 - (45) cystyl;

A₇ is an amino acyl residue of L or D configuration selected from:

- (1) alanyl,
- (2) allylglycyl,
- (3) aspartyl,
- (4) citrullyl,
- (5) cyclohexylglycyl,
- (6) glutamyl,
- (7) glycyl,
- (8) homoseryl,
- (9) isoleucyl,
- (10) allo-isoleucyl
- (11) leucyl,
- (12) lysyl(N-epsilon-acetyl),
- (13) methionyl,
- (14) 3-(naphth-1-yl)alanyl,
- (15) 3-(naphth-2-yl)alanyl,
- (16) norvalyl,
- (17) phenylalanyl,
- (18) prolyl,
- (19) seryl,
- (20) *t*-butylglycyl,
- (21) tryptyl,
- (22) tyrosyl,
- (23) valyl,
- (24) D-allo-isoleucyl,

- (25) D-isoleucyl,
(26) penicillamanyl, and
(27) cystyl;

A₈ is an amino acyl residue selected from:

- (1) 2-amino-4-[(2-amino)-pyrimidinyl]butanoyl,
(2) alanyl(3-guanidino),
(3) alanyl[3-pyrrolidinyl(2-N-amidino)],
(4) alanyl[4-piperidinyl(N-amidino)],
(5) arginyl,
(6) arginyl($N^G N^G$ diethyl),
(7) citrullyl,
(8) 3-(cyclohexyl)alanyl(4-N-isopropyl),
(9) glycyl[4-piperidinyl(N-amidino)],
(10) histidyl,
(11) homoarginyl,
(12) lysyl,
(13) lysyl(N-epsilon-isopropyl),
(14) lysyl(N-epsilon-nicotinyl),
(15) norarginyl,
(16) ornithyl(N-delta-isopropyl),
(17) ornithyl(N-delta-nicotinyl),
(18) ornithyl[N-delta-(2-imidazolinyl)],
(19) [(4-amino(N-isopropyl)methyl)phenyl]alanyl,
(20) 3-(4-guanidinophenyl)alanyl, and
(21) 3-(4-amino-N-isopropylphenyl)alanyl;

A₉ is an amino acyl residue of L or D configuration selected from:


- (1) 2-amino-butyryl,
(2) 2-amino-isobutyryl,
(3) homoprolyl,
(4) hydroxyprolyl,
(5) isoleucyl,
(6) leucyl,
(7) phenylalanyl,
(8) prolyl,

- AJ*
- (9) seryl,
 - (10) *t*-butylglycyl,
 - (11) 1,2,3,4-tetrahydroisoquinoline-3-carbonyl,
 - (12) threonyl,
 - (13) valyl,
 - (14) D-alanyl, and
 - (15) D-prolyl; and

A_{10} is a hydroxyl group or an amino acid amide is selected from:

azaglycylamide,
D-alanyl amide,
D-alanylethylamide,
glycylamide,
glycylethylamide,
sarcosylamide,
seryl amide,
D-seryl amide,

a group represented by the formula



a group represented by the formula $-\text{NH}-\text{R}^4$;

wherein:

s is an integer selected from 0 to 8,

R^2 is selected from hydrogen, alkyl, and a 5- to 6-membered cycloalkyl ring;

R^3 is selected from hydrogen, hydroxy, alkyl, phenyl, alkoxy, and a 5- to 6-membered ring optionally containing from one to two heteroatoms selected from oxygen, nitrogen, and sulfur, provided that s is not zero when R^3 is hydroxy or alkoxy; and

R^4 is selected from hydrogen, hydroxy, and a 5- to 6-membered cycloalkyl ring.

Please add the following new claims:

AJ

18 (New). A compound, or a pharmaceutically acceptable salt, ester, solvate, or prodrug thereof, selected from the group consisting of

N-Ac-Sar-Gly-Val-D-Ile-Thr-Nva-Ile-Arg-ProNHCH₂CH₃,

N-Ac-Sar-Gly-Val-D-*allo*Ile-Thr-Nva-Ile-Arg-ProNHCH₂CH₃,

A2
Cont.

N-Ac-Sar-Gly-Val-D-Ile-Thr-Gln-Ile-Arg-ProNHCH₂CH₃, and
N-Ac-Sar-Gly-Val-D-alloIle-Ser-Ser-Ile-Arg-ProNHCH₂CH₃.

19 (New). The compound, or pharmaceutically acceptable salt, ester, solvate, or prodrug thereof, which is N-Ac-Sar-Gly-Val-D-Ile-Thr-Nva-Ile-Arg-ProNHCH₂CH₃.

20 (New). The compound, or pharmaceutically acceptable salt, ester, solvate, or prodrug thereof, which is N-Ac-Sar-Gly-Val-D-alloIle-Thr-Nva-Ile-Arg-ProNHCH₂CH₃.

21 (New). The compound, or pharmaceutically acceptable salt, ester, solvate, or prodrug thereof, which is N-Ac-Sar-Gly-Val-D-Ile-Thr-Gln-Ile-Arg-ProNHCH₂CH₃.

22 (New). The compound, or pharmaceutically acceptable salt, ester, solvate, or prodrug thereof, which is N-Ac-Sar-Gly-Val-D-alloIle-Ser-Ser-Ile-Arg-ProNHCH₂CH₃.

23 (New). A composition comprising a compound, or a pharmaceutically acceptable salt, ester, solvate, or prodrug thereof, selected from the group consisting of

N-Ac-Sar-Gly-Val-D-Ile-Thr-Nva-Ile-Arg-ProNHCH₂CH₃,

N-Ac-Sar-Gly-Val-D-alloIle-Thr-Nva-Ile-Arg-ProNHCH₂CH₃,

N-Ac-Sar-Gly-Val-D-Ile-Thr-Gln-Ile-Arg-ProNHCH₂CH₃, and

N-Ac-Sar-Gly-Val-D-alloIle-Ser-Ser-Ile-Arg-ProNHCH₂CH₃,

and a pharmaceutically acceptable carrier.

24 (New). A composition comprising
N-Ac-Sar-Gly-Val-D-Ile-Thr-Nva-Ile-Arg-ProNHCH₂CH₃, or a pharmaceutically acceptable salt, ester, solvate, or prodrug thereof, and a pharmaceutically acceptable carrier.

25 (New). A composition comprising
N-Ac-Sar-Gly-Val-D-alloIle-Thr-Nva-Ile-Arg-ProNHCH₂CH₃, or a pharmaceutically acceptable salt, ester, solvate, or prodrug thereof, and a pharmaceutically acceptable carrier.

26 (New). A composition comprising

Original
Copy

N-Ac-Sar-Gly-Val-D-Ile-Thr-Gln-Ile-Arg-ProNHCH₂CH₃, or a pharmaceutically acceptable salt, ester, solvate, or prodrug thereof, and a pharmaceutically acceptable carrier.

27 (New). A composition comprising
N-Ac-Sar-Gly-Val-D-alloIle-Ser-Ser-Ile-Arg-ProNHCH₂CH₃, or a pharmaceutically acceptable salt, ester, solvate, or prodrug thereof, and a pharmaceutically acceptable carrier.

28 (New). A composition for the treatment of a disease selected from cancer, arthritis, psoriasis, angiogenesis of the eye associated with infection or surgical intervention, macular degeneration, and diabetic retinopathy comprising a compound, or a pharmaceutically acceptable salt, ester, solvate, or prodrug thereof, selected from the group consisting of

N-Ac-Sar-Gly-Val-D-Ile-Thr-Nva-Ile-Arg-ProNHCH₂CH₃,
N-Ac-Sar-Gly-Val-D-alloIle-Thr-Nva-Ile-Arg-ProNHCH₂CH₃,
N-Ac-Sar-Gly-Val-D-Ile-Thr-Gln-Ile-Arg-ProNHCH₂CH₃, and
N-Ac-Sar-Gly-Val-D-alloIle-Ser-Ser-Ile-Arg-ProNHCH₂CH₃,

and a pharmaceutically acceptable carrier.

29 (New). A composition for the treatment of a disease selected from cancer, arthritis, psoriasis, angiogenesis of the eye associated with infection or surgical intervention, macular degeneration, and diabetic retinopathy comprising
N-Ac-Sar-Gly-Val-D-Ile-Thr-Nva-Ile-Arg-ProNHCH₂CH₃, or a pharmaceutically acceptable salt, ester, solvate, or prodrug thereof, and a pharmaceutically acceptable carrier.

30 (New). A composition for the treatment of a disease selected from cancer, arthritis, psoriasis, angiogenesis of the eye associated with infection or surgical intervention, macular degeneration, and diabetic retinopathy comprising
N-Ac-Sar-Gly-Val-D-alloIle-Thr-Nva-Ile-Arg-ProNHCH₂CH₃, or a pharmaceutically acceptable salt, ester, solvate, or prodrug thereof, and a pharmaceutically acceptable carrier.

31 (New). A composition for the treatment of a disease selected from cancer, arthritis, psoriasis, angiogenesis of the eye associated with infection or surgical intervention, macular degeneration, and diabetic retinopathy comprising